399
104194226014562116179
PŘEHLEDOVÝ852207016974156235334409485586692777867
ČLÁNEK1757207016989163260360438521
Ces8507936014570127174
Urol10497936014578115180208
2020;12827936014562121178237261
24(2):15697936014561118151210240262
100–10418567936014562117179243296351413
7.85089601335668
Meye938896013388144195248
A,120689601336892
Bilkenroth131889601336085111161214275310370406466
U,180489601337191
Schmidt1915896013354103163254279341377
U,231289601337191
et242389601335591
al.253589601335378100
Isolation266089801312059117140189221243301359
and3040898013150108167
enrichment3228898013153111142165213271360413471503
of375189801315987
urologic385989801315890146169227287309357
tumor424189801313088177235267
cells4529898013149100122144183
in473689801312077
blood483489801316084142201261
sam‑511989801313888177210
ples850104801316184137177
by10511048013161108
a11831048013150
semi‑automated1257104801314194183205238287344377433523572604655715
CD4519961048013163132187237
depletion22571048013160113172195248281303361420
autoMACS27011048013150107140196281345405456
protocol.3181104801316193150182238287343367385
Int3590104801312381113
J37271048013138
Oncol37891048013174133181237260
2002;40731048013154106161210228
21:43251048013154101112
521–530.44611048013154104151200252301354371
8.850119601335678
Bluemke945119601335984142195284334385
K,1347119601336084
Bilkenroth1448119601335983107155207266300358392450
U,1915119601337189
Meye20211196013388142191243
A,2281119601336790
et2388119601335590
al.249511960133537697
Detection26101198013171123154204251286307363419
of3047119801315885
circulating315011980131496999144199220267297318374432
tumor3604119801312985172229259
cells3881119801314998119139176
in4080119801311874
peripheral41711198013161113143164222279330360408429
blood4618119801316082138195254
of4889119801315985
patients49921198013160109139160211267297337
with8501348013179101133190
renal1063134801313181138186207
cell1291134801314999121141
carcinoma1453134801315098128174195251308397445
correlates19191348013149104135166216238285316366405
with23461348013179101133190
prognosis.2557134801316192147206263320359379417435
Cancer30141348013163111168215265295
Epidemiol33311348013151109130188240328349406428
Biomarkers3780134801315576133222269299345395425465
Prev.4267134801315584135182194
2009;44831348013153104158210228
18:4732134801315499116
2190–2194.48691348013154100144197254300346390443460
9.850149601335675
Shimazui9491496013354114139230283330390415
T,1387149601335571
Yoshikawa14811496013360113156216241292346425478
K,1982149601336085
Uemura20911496013371125217277312365
H,2479149601337295
et2597149601335592
al.2712149601335379101
Detection28371498013171125158209258295317374433
of3294149801315987
cadherin-63405149801314999158216269301323381414471
mRNA39001498013190145215278
by42021498013161108
nested43341498013159112152187238298
RT‑PCR46561498013156107134190252306
as4986149801315090
a51001498013150
po‑51741498013160120155
tential850164801313485143175197245267
marker11411648013190139171217268300
for1465164801312986118
circulating1607164801314971102149206228277309331389448
cancer2079164801314999157205256287
cells2391164801314999122144183
in2598164801312380
renal2702164801313384142191213
cell29391648013149100123144
carcinoma.3108164801314998130176198256314403452471
Int3604164801312380112
J37401648013138
Oncol38021648013174133182238261
2003;40871648013153105160210227
23:43381648013153106122
1049–1054.44841648013154101156206263309356408461479
10.8501796013356107129
Li1002179601335277
G,1102179601337195
Passebosc‑Faure12191796013359110153195251313374416466493549597657692746
K,1988179601336085
GentilPerret20961796013371127188223248273331384419455510546
A,2665179601336792
et2780179601335591
al.2894179601335378101
Cadherin-630181798013163112172230283314337394428485
gene35261798013160113171224
expression37731798013154101162194245285325346404463
in4260179801312280
conventional43631798013149105164211263321353375432491540562
renal4949179801313283141190212
cell51851798013149100122144
carcinoma:850194801314999130177199256314404453470
a13441948013150
useful1418194801315998151179238260
marker17021948013190139170217268300
to2026194801313490
detect21401948013160112146197246282
circulating2446194801314971102149206229277309331389448
tumor2918194801313492181239271
cells.32131948013150100123145183203
Anticancer34401948013164123154176225274332381432463
Res.39271948013156109149168
2005;41201948013153105160211227
25:43711948013154107122
377–381.45171948013154102154203251304351364
11.8502096013356101118
Buchner9902096013359119168229289344380
A,1391209601336792
Riesenberg1504209601335985140183238299361416452513
R,2038209601335984
Kotter21442096013359118154192246282
I,2449209601332447
et2518209601335591
al.2630209601335379101
Frequency2753209801315180131191248301359408459
and32342098013150107167
prognostic3423209801316193149209267325365400422470
relevance3917209801313182105158206256314363413
of4352209801315987
disseminated4461209801316082121161214303325382431463514574
tumor5059209801313290179237269
cells8502248013149100123144183
in1057224801312381
bone11622248013160120178231
marrow14172248013190139171203259338
of1779224801315887
patients18902248013160110143165217275307349
with22632248013179102135193
metastatic24802248013190143176226266300350382404452
renal2957224801313284141190212
cell31932248013150100123145
carcinoma.3362224801314999130177198256314404453472
Cancer38582248013162112170219269301
2006;41832248013154105160215233
106:44402248013154101155173
1514–1520.4637224801315398145191248294339389440458
12.8502396013356104126
Basso9952396013360113155197257
U,1271239601337190
Facchinetti13802396013354102150197257281341396432470494
A,1894239601336791
Rossi20042396013359119161203228
E,2251239601335476
et2346239601335591
al.2456239601335378100
Prognostic2577239801315585141201258316356390411459
role3060239801312985107160
of3240239801315886
circulating3346239801314970101147204226274306328385444
tumor3813239801313088176234265
cells‑CTCs4098239801314999122143182213278332390432
in4553239801311976
metastatic46492398013190143175225264298347379401449
renal5121239801312980137186208
cell8502548013149100123144
carcinoma.1018254801314999130177199256315404453472
J15142548013138
Clin1576254801316385106164
Oncol.17642548013174133181237260279
2017;20672548013154105153196210
35:23012548013154104119
4568–4568.24442548013153103155209265321371422476496
13.8502696013356105126
Krebs1000269601336097151213256
MG,12802696013388159183
Metcalf14862696013389144181228281307339
RL,18482696013360112135
Carter20072696013364117152191245280
L,2311269601335276
et2410269601335592
al.2525269601335379101
Molecular26512698013186144167220269327349397429
analysis31042698013150108157179227267289328
of3456269801315987
circulating3567269801314971102149206229277309331389448
tumour4039269801313593181240298329
cells‑biology43922698013149100123145183214275298356379437497546
and49622698013150108167
bio‑5154269801316083141176
markers.8502848013190139170216268299340360
Nat12342848013170119151
Rev14092848013156109158
Clin1591284801316384106163
Oncol.17792848013173132181237260278
2014;20812848013154106153200217
11:2322284801315495106
129–144.2452284801315498150207253300356374
14.8502996013356106128
Palumbo9992996013359110136195287349409
JS,1432299601333892114
Talmage15672996013355100125216269330385
KE,19732996013360115137
Massari21322996013388141184226280315340
JV,24962996013338100116
et2633299601335692
al.2746299601335379101
Platelets2869299801315576125157208231283317358
and32492998013150108167
fibrin(ogen)3438299801312754113145168225253308368421479504
increase3966299801312178127158210258298351
metastatic43392998013190143176226265300350382404452
potential48132998013161120152203261293315363386
by52212998013160107
impeding8503148013123112171225286307365424
natural12983148013159108140198229279301
killer162331480131477193115167199
cell‑mediated18463148013149100122144177268321381403451483534594
elimination246531480131537697186208265314346368426484
of2973314801315987
tumor3084314801313492181239271
cells.33793148013150100123145183203
Blood3606314801315678136195256
2005;38863148013153105160212227
105:41373148013154101153168
178–185.4329314801315497148204250297348365
15.8503296013356104125
Zhang9943296013361120172232293
D,1306329601337392
Zhao14173296013360120172231
L,1667329601335275
Zhou17623296013360120179239
P,2020329601335968
et2107329601335591
al.2217329601335378100
Circulating2338329801316284115161218240288320342399458
tumor2819329801313088176234265
microemboli31043298013190111159190246300388448506529550
(CTM)3678329801312584138222249
and39463298013150107166
vimentin+4132329801315072160213271302324381444
circulating4596329801314970101148204226274306328385444
tumor5064329801313087175233265
cells8503448013149100123144183
(CTCs)1057344801313897152211253278
detected13593448013167120154205254290341402
by17853448013169116
a19253448013158
size‑based2007344801314970114166201262312352405465
platform2496344801316992141173205262294384
predict29043448013169101153213235283319
worse32553448013180137169210264
prognosis35433448013168100157217275334374395434
in4001344801313189
advanced41143448013158117167217275323374435
colorectal45733448013157113136194226278327363413435
cancer50323448013157107165214265296
patients8503598013161111143165217275307349
during12233598013160117148171228288
chemotherapy.15353598013149106160249307339397450482532591639652
Cancer22113598013163113170219270301
Cell25363598013163114137158
Int.2718359801312481113132
2017;28743598013154106153197210
17:3109359801315397111
6.3244359801315372
16.8503746013356103123
Hou9873746013371129186
JM,11873746013340125146
KrebsMG,1347374601335993145204243345413434
Lancashire17953746013351102160206255295352374406458
L,2267374601335172
et2353374601335588
al.245637460133527594
Clinical2566374801316281100154173218265284
significance2865374801314159115170189212238283330385430478
andmolecular33583748013149104160264319340389436490509555583
characteristics39563748013148103149177224269303350379399435466486531569
of4540374801315884
circulating463937480131486795139193213258287307361417
tumor5071374801313488174229258
cells850389801314998118138174
and10433898013150106163
circulating122538980131506998143198218264294314369427
tumor1673389801313287174230260
microemboli19523898013190110156185240291378436493513533
in2507389801312075
patients26023898013160108138158208264294333
with29543898013180100131187
small‑cell31603898013141128174194214245294342363382
lung3564389801312175131188
cancer.3771389801315097153199248277289
J40823898013135
Clin4136389801316383102157
Oncol.43123898013174131177231252268
2012;45993898013154103149191207
30:48253898013154104121
525–532.49653898013154101152205254302348364
17.8504046013356104115
Nagaya9874046013373126187239289342
N,1351404601337295
Kanayama14684046013360114174227276329420473
M,19634046013388112
Nagata20984046013372125186238274327
M,24474046013389113
Horie25824046013372132168193248
S.2853404601335477
The29534048013151111164
Surge31404048013151108139197250
in3414404801312279
the3518404801313290144
Number36854048013170127216276330361
of4069404801315987
Circulating4179404801316385116163220242291323345403462
Tumor46644048013151101190248280
Cells49674048013163114137158197
Fo‑51874048013151108142
llowing850419801312345103181204261320
Treatment1191419801315176127175207296350407439
with16514198013179101135193
Sunitinib18644198013151108166187220243300322381
for2269419801312582114
Metastatic24044198013185138171221261295345377399447
Renal28724198013155108166215237
Cell31294198013163114136158
Carcinoma.33084198013162112143190212269327417466485
Intern3817419801311977109160191250
Med.40874198013186139199218
2018;43254198013154105153199217
57(18):45634198013153104127175221247264
2695–2700.48474198013154105156208263310360409464482
◼8807048016456
Urologická10007049013169100156179237298319368413464
léčba1488704901312376125185235
roztroušené1747704901313289131168200256314353406464517
sklerózy2288704901314186110163195251293345
◼8807198016456
Léčba10007199013149101150210260
následků12847199013159107147169222282327385
dlouhodobě1693719901316082140198256314375433493547
navlečeného22647199013159108155178231280331389442500558
perlátoru28467199013161115147170218250306338397
na32677199013159107
kořen33987199013147104136187245
penisu36677199013161115173194233290
◼8807348016456
Prevence1000734901315586137186238296344395
recidivujících1419734901313384134155215236286344366388436458506563
cystitid20067349013149100141175198231253312
pomocí23427349013161120210268318339
roztoku2705734901313389132169225271329
hyaluronátu30587349013159105155177234265322380429461519
sodného3601734901314199160217270328387
◼8807498016456
Segmentální10007499013151104164253307364396446468525547
infarkt1571749901312381108159190236273
varlete:18687499013150100131154207240291309
orchiektomie2201749901315890137195216269315351407497519571
vs.2796749901315091110
sledování2930749901314163116176234283332390412
◼8807648016456
Parciální10007649013155103135181203251274331353
amputace13777649013150139198256290339388439
penisu18407649013161115173194233290
jako2154764901312372117174
léčba2352764901312376125185235
verukózního26117649013149101133191236293335394416476534
karcinomu3169764901314797129175197255313403460
Do85060800402227414
České132760800402193358502685850
urologie22416080040219131950659878697510681238
č.354360800402144236
3384260800402183
/406560800402105
2020421060800402183362538718
připravujeme85064200402195323413607735905107312621358152918081979